Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2020-05-11 Board/Management Inform…
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short announcement dated May 11, 2020, informing about a scheduled Board Meeting on May 20, 2020, to consider and approve audited financial results for the quarter and year ended March 31, 2020, and recommendation of dividend. It also mentions the closure of the trading window as per insider trading regulations. The document does not contain any financial data or results itself, but is a notification of an upcoming board meeting where such results will be considered. The length is only 1562 characters, indicating it is a brief announcement rather than a full report. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements of board meetings and related management information.
2020-05-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release issued by Strides Pharma Science Limited announcing the development and commencement of export of Favipiravir Antiviral Tablets. It contains no financial statements, regulatory filings, or detailed financial data. It is a public announcement about a product development and commercial activity, not a financial report or regulatory filing. The document is approximately 6,842 characters, which is relatively short and consistent with a press release. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit into other specific categories like earnings release or capital update.
2020-04-29 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for Flucytosine Capsules. It is addressed to stock exchanges and includes details about the product approval, market size, manufacturing location, and company background. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document is a corporate announcement about a regulatory approval event, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the approval event itself. Therefore, the most appropriate classification is a Capital/Financing Update (CAP) as it relates to a significant regulatory approval impacting the company's product portfolio and market potential, which is often categorized under capital or business updates.
2020-04-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated April 2, 2020, from Strides Pharma Science Limited. It provides updates on the USFDA's request to withdraw all Ranitidine products from the US market. The content focuses on regulatory developments, product status, and business outlook related to this event. There are no financial statements, detailed financial analysis, or comprehensive reporting typical of annual or interim reports. The document is an official company announcement about a regulatory and product issue, not a financial report or detailed management discussion. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2020-04-02 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a US FDA inspection at the company's flagship facility. It does not contain financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is relatively short (3896 characters) and serves as a public announcement of an operational milestone rather than a detailed report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a certification, voting result, or management change announcement. The best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2020-03-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a short announcement informing stock exchanges about the receipt of an Establishment Inspection Report (EIR) from the USFDA confirming the successful closure of an inspection at the company's facility. It does not contain financial data, detailed reports, or regulatory filings beyond this notification. The length is only 1181 characters, indicating it is a brief notice rather than a full report. It is an informational update to the exchanges, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-03-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.